ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock Has Consensus Target Price of $99.60 According to Analysts

Posted by George Bondi on Nov 5th, 2026

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) has earned a consensus rating of “Hold” from the seven analysts that are currently covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $99.60.

Several research firms have recently issued reports on ANIP. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Canaccord Genuity Group decreased their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Guggenheim lowered their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Oppenheimer assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They set a “market perform” rating and a $85.00 target price for the company.

Read Our Latest Report on ANIP

Insider Buying and Selling at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, October 13th. The shares were sold at an average price of $73.59, for a total transaction of $36,795.00. Following the completion of the transaction, the vice president directly owned 73,424 shares of the company’s stock, valued at $5,403,272.16. This trade represents a 0.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the transaction, the senior vice president owned 75,534 shares of the company’s stock, valued at $5,816,118. This represents a 4.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 30,412 shares of company stock worth $2,220,970. 8.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. KBC Group NV purchased a new stake in ANI Pharmaceuticals in the 1st quarter valued at about $28,000. Versant Capital Management Inc lifted its holdings in shares of ANI Pharmaceuticals by 103.3% during the 3rd quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 217 shares during the period. USA Financial Formulas purchased a new position in shares of ANI Pharmaceuticals during the 3rd quarter worth about $39,000. Sterling Capital Management LLC lifted its holdings in shares of ANI Pharmaceuticals by 850.0% during the 3rd quarter. Sterling Capital Management LLC now owns 684 shares of the specialty pharmaceutical company’s stock worth $50,000 after acquiring an additional 612 shares during the period. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of ANI Pharmaceuticals in the second quarter worth approximately $76,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 0.9%

ANIP opened at $71.65 on Monday. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. ANI Pharmaceuticals has a 12 month low of $69.58 and a 12 month high of $95.57. The stock has a market capitalization of $1.65 billion, a P/E ratio of 15.44, a P/E/G ratio of 2.33 and a beta of 0.45. The business has a 50 day simple moving average of $72.74 and a 200-day simple moving average of $77.49.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last released its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. ANI Pharmaceuticals’s revenue was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts anticipate that ANI Pharmaceuticals will post 7.76 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

(Get Free Report)

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.